Company Overview

Alterity Therapeutics Limited is a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies for neurodegenerative disorders. The company operates within the biotechnology and pharmaceutical research industries, with a primary emphasis on conditions characterized by abnormal protein aggregation in the brain. Alterity’s lead programs target Multiple System Atrophy (MSA) and Parkinson’s disease, areas with significant unmet medical need and limited therapeutic options.

The company’s core value proposition is centered on its proprietary small-molecule drug candidates designed to modulate metal-protein interactions implicated in neurodegeneration. Alterity Therapeutics was originally founded in Australia as Prana Biotechnology Limited in 1997 and rebranded to its current name in 2019 to reflect a strategic refocus on alpha-synuclein–related disorders. Since its inception, the company has evolved from broad neurodegenerative research to a more targeted clinical development strategy.

Business Operations

Alterity Therapeutics’ operations are primarily organized around its clinical development programs, with revenue generation currently limited as the company does not have approved commercial products. Its principal asset is ATH434, a small-molecule compound designed to reduce pathological alpha-synuclein aggregation by restoring neuronal iron balance. ATH434 is being evaluated in clinical trials for Multiple System Atrophy (MSA) and has also been studied in Parkinson’s disease.

The company conducts research and development activities across Australia and the United States, leveraging a combination of internal expertise and outsourced clinical research organizations. Alterity Therapeutics does not report material operating subsidiaries beyond its wholly owned operating entities and has not disclosed major joint ventures generating revenue. Its operations are funded primarily through equity offerings, government research grants, and investor capital.

Strategic Position & Investments

Alterity Therapeutics’ strategy is focused on advancing ATH434 through mid-stage and late-stage clinical development while expanding the scientific understanding of metal dysregulation in neurodegenerative disease. The company prioritizes indications with high unmet need and regulatory pathways that may support orphan drug designation and expedited development.

Historically, Alterity has made targeted investments in preclinical and translational research rather than large-scale acquisitions. The company’s strategic repositioning from Prana Biotechnology to Alterity Therapeutics marked a narrowing of its portfolio to alpha-synucleinopathies. As of the latest publicly available disclosures, no material acquisitions or diversified portfolio companies have been reported, and investment activity remains concentrated on internal drug development.

Geographic Footprint

Alterity Therapeutics is headquartered in Melbourne, Australia, with a significant operational and corporate presence in the United States, including executive leadership and clinical development activities. The company’s securities are publicly traded on both the NASDAQ in the United States and the Australian Securities Exchange, providing access to international capital markets.

Clinical trials and research collaborations extend across North America, Europe, and Australia, reflecting the global nature of patient recruitment and regulatory engagement in rare neurodegenerative diseases. While the company does not maintain large-scale manufacturing operations, its international footprint supports regulatory, clinical, and investor-facing activities across multiple regions.

Leadership & Governance

Alterity Therapeutics is led by an executive team with experience in biopharmaceutical development, clinical research, and public company governance. The leadership emphasizes a science-driven approach, disciplined capital allocation, and advancing therapies for diseases with limited treatment options.

Key executives include:

• David Stamler – President and Chief Executive Officer
• David Brenner – Chief Financial Officer
• Ubaldo Armato – Chief Scientific Officer
• Lars Ekman – Chief Medical Officer
• Geoffrey Kempler – Non-Executive Chairman of the Board